Rexahn announces clinical collaboration with Merck to evaluate RX-5902 (Supinoxin™)
Rexahn Pharmaceuticals announced a clinical trial collaboration agreement with Merck to evaluate the combination of Rexahn’s RX-5902 and Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in a Phase 2 trial in patients with metastatic triple negative breast cance. August 21, 2018